Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

pt Corporation and Subsidiaries(Unaudited)Selected Consolidated Statement of Cash Flows Data(in $000s)Six Months Ended June 30,20132012Net cash used in operating activities

$
(1,402)

$
(2,599)Net cash provided by investing activities

308

—Net cash provided by financing activities1,138

1,003Effect of exchange rate changes on cash

(16)

(9)Net increase (decrease) in cash and cash equivalents 

28

(1,605)Cash and cash equivalents at beginning of  period

172

6,378Cash and cash equivalents at end of  period

$
200

$
4,773
 EpiCept Corporation and Subsidiaries(Unaudited)Selected Consolidated Statement of Stockholders' Deficit Data(in $000s)Six Months Ended June 30,20132012Stockholders' deficit at beginning of  period

$
(13,969)

$
(17,146)Net loss for the period

(2,784)

(569)Stock-based compensation expense

88

404Foreign currency translation adjustment

(16)

257Share and warrant issuance

500

2,833Warrant amendment expense

936Exercise of warrants

728Stockholders' deficit at end of  period

$  (16,181)

$  (12,557) 

As of July 31, 2013, EpiCept had 114,159,030 common shares outstanding.EpiCept expects to report interim results for the three months ending September 30, 2013 on or about November 15, 2013

 


'/>"/>
SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
(Date:12/22/2014)... December 22, 2014 ITRA Global, one ... occupiers of commercial real estate, has further expanded its ... in Perth and Brisbane, Western Australia, reports Mylinda Vick, ... , ITRA Global / ACORPP (Australian Corporate Property ... consultancy company providing property services to a wide range ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Highlights Include Clinical Trial Updates, BETHESDA, Md., ... NWBT; OTC Bulletin Board: NWBO), (the,"Company or NWBT"), ... and Chief Executive Officer, will deliver a presentation ... vaccines for the,treatment of cancer, at the "Next ...
... (July 17, 2008) Researchers at the U.S. Department of ... have won two R&D 100 Awards for innovative fluid ... been awarded 101 R&D 100 Awards since the awards ... R&D 100 Award -- dubbed the "Oscars of innovation" ...
... Opens at The O2 This Autumn, - With ... exhibition to premiere at The O2, Body,Worlds & The ... von Hagens, go on sale today., (Photo: ... In partnership with the producers of the sensation ...
Cached Biology Technology:Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 2Tickets for Brand New Exhibition 'Body Worlds & The Mirror of Time' on Sale 18 July 3
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... approach can kill bacteria in laboratory experiments and eliminate ... bacterial nutrient, according to research led by a University ... UW, the University of Iowa, and the University of ... of the Journal of Clinical Investigation. , Bacteria ...
... bacterial composition of the oral cavity even in low doses. ... needed to counteract the production of acid between the teeth, ... defend at UmeƄ University in Sweden on February 23. , ... of the sugar xylose, or wood sugar. Xylitol occurs ...
... respond to a flash of light are providing insight into ... yield a better understanding of how the human brain works. ... Hughes Medical Institute have engineered a strain of mice whose ... accomplished by inserting into the cells a gene naturally present ...
Cached Biology News:Trojan horse strategy defeats drug-resistant bacteria 2Xylitol reduces risk of cavities 2Common algae helps illustrate mammalian brain electrical circuitry 2Common algae helps illustrate mammalian brain electrical circuitry 3
... the needs of the biopharmaceutical ... supports fast cell growth rates ... maintaining high cell viability and ... the Baculovirus Expression Vector System ...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... Ek Adaptor encodes a T7 promoter, ... ATG translation initation codon, and an N-terminal ... 109 aa sequence that encodes thioredoxin. Fusion ... enhance solubility of many proteins that are ...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
Biology Products: